Huanxin Medical Completes Series B Financing to Advance Innovative Interventional Device Portfolio

Aug 15, 2025 18:04 CST Updated 18:04

CardioCycle

Innovative Medical Device Developer

Instrument Family

Pioneer in Medical Device Media Reports

Share Professional Medical Device Knowledge

Source:TianChao Capital Official Website, YiZhou

August 15th, news came that CardioCycle Technology (Suzhou) Co., Ltd. ("CardioCycle") announced the completion of its Series B financing round. The investors include Daoyuan Capital, Ruihua Holdings, and TF Capital. This round of financing will help CardioCycle accelerate product development and market expansion, further solidifying its leading position in the interventional medical device field.

CardioCycle Technology (Suzhou) Co., Ltd. was established in 2020 and is an innovative medical device developer specializing in the research and development of interventional medical devices.The company is committed to the research and development, manufacturing, and innovation in related technical fields of interventional medical devices. Its products cover structural heart disease and surgical accessories, as well as interventional vascular access products, establishing a comprehensive product portfolio and solutions in the field of structural heart disease and vascular intervention in China.

CardioCycle was co-founded by core engineers of medical devices, clinical experts, and capital investors. The company focuses on providing one-stop solutions for precise interventional treatments, covering cardiac interventions and peripheral vascular interventions. Production and R&D centers have been established in Biobay, Suzhou, and GMIT, Galway, Ireland. The company is committed to becoming an interventional medical solutions provider specializing in R&D and manufacturing, serving patients and contributing globally.

CardioCycle's core product lines focus on the cardiovascular and pan-vascular intervention fields, mainly divided into the following three categories:

Cardiovascular Interventional Devices: OccluFar SealFlex® Balloon Occlusion Microcatheter, a pioneering product in China, features an integrated "delivery + occlusion" function. It is suitable for tumor interventional treatments (such as TACE procedures for liver cancer) and is one of the top three similar products globally, filling a gap in the Chinese market. Corsharp BoYu® Transseptal Puncture System, used for transseptal puncture operations during cardiac interventional procedures, has been approved for marketing. Corbend BoXiang® Steerable Sheath System provides precise catheter guidance and support, adaptable to complex vascular pathways. RadialFar RaoYou® / MicroFar CongYou® Microcatheters, designed respectively for radial artery/femoral artery interventional approaches. SteerFar QuYou® Steerable Microcatheter enhances intraoperative maneuverability.
Peripheral Vascular Intervention Devices: AccuFar BenYou™ Micro Guidewire, approved for marketing in November 2024, available in three diameter specifications of 0.014"/0.016"/0.018" and 21 length models, featuring excellent torque control, strong tip compliance, and a hydrophilic coating along the entire body to reduce friction. Corpassing BoHuai® Catheter Sheath Set, a core tool for establishing vascular access. Corflow BoHan® Balloon Dilatation Catheter, used for endovascular angioplasty.
Implantable Devices: Polyvinyl Alcohol Embolization Microspheres for Tumor Vascular Embolization Therapy.

END

High-End Medical Imaging Project Lands in Suzhou

Medtronic: To Invest in China's Start-up Device Companies

Siemens Healthineers Teams Up with "The King of Gaming"

Deepening Interventional Imaging, GE Healthcare Achieves Strategic Collaboration

144 Billion Medical Device Giant, Going Public in Hong Kong

87 Sets of Ultrasound Equipment Procurement: Mindray and Neusoft Secure the Deal

Philips Reduces Stake in China's Leading Medical Company

$16.1 Billion: Bezos and Johnson & Johnson Team Up to Acquire Medical Device Company

A-share Medical Device Leader Enters Intelligent Robotics

Clinical Trials Begin: United Imaging Photon Counting CT Arrives

BusinessBusiness cooperation email: qxzj@landianyiliao.com